Notícias e Atividades da Orchard Therapeutics

A Orchard Therapeutics pertence à Kirin.

Kirin é uma das ...

• Forbes Global 2000 (#1079);
• Nikkei 225;
• TOB Iconic 10,000;
• Topix.

Kirin é uma empresa listada sob o símbolo 2503 (JP).

Kirin tem presença direta em 3 países.

Kirin possui 6 subsidiárias incluindo Coca-Cola Beverages Northeast, Kyowa Chemical Industry e Kyowa Hakko Kirin.

Eles estão dentro:

• Bebidas29%
• Farmacêutica29%
• Outro43%

Veja o organograma con seus 13 executivos principais

Biografias mais buscadas da Orchard Therapeutics

• Bobby Gaspar, Chief Executive Officer and Director
• Nicoletta Loggia, Chief Technical Officer
• Robin Kenselaar, Chief Commercial Officer

Criar um alerta
para seguir os movimentos de executivos da Orchard Therapeutics.

Kirin possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Orchard Therapeutics

• Crossing the Blood-Brain Barrier to Treat Disease - Orchard Therapeutics
• News & Press Releases | Orchard Therapeutics
• Landmark Studies Shine A Light on the Need to Modernize the US Newborn Screening System - Orchard Therapeutics
• Rightsizing the U.S. Newborn Screening System – Orchard Therapeutics
• Orchard Therapeutics Receives Positive CHMP Opinion for Libmeldy™ for the Treatment of Early-Onset Metachromatic Leukodystrophy (MLD) | Orchard Therapeutics
• Orchard Therapeutics Receives EMA PRIME Designation for OTL-203 for the Treatment of MPS-I | Orchard Therapeutics
• Orchard Therapeutics to Present at Upcoming Virtual Investor Conferences | Orchard Therapeutics
• Orchard Therapeutics Announces Additional Interim Results from Proof-of-Concept Study of OTL-203 for MPS-I | Orchard Therapeutics
• Orchard Therapeutics Announces Clinical Data Presentations at the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) | Orchard Therapeutics
• Press Releases | Orchard Therapeutics
• View more press releases Close

Redes sociais sobre Orchard Therapeutics

• Orchard Therapeutics na Wikipedia, Google News e Yahoo Finance
• Orchard Therapeutics na LinkedIn, X (Twitter) e YouTube